We are delighted to be featured on the 2024 edition of The Sunday Times Hundred, Britain's fastest-growing private companies. The league table takes on the baton from The Sunday Times Fast Track 100 series, which celebrated the country's leading entrepreneurs for 24 years. See the list here: https://lnkd.in/e_ufZH-U
Cycle Pharmaceuticals
Pharmaceutical Manufacturing
Cambridge, Cambridgeshire 9,004 followers
Every Single Patient Matters.
About us
We’re committed to supporting patients and their caregivers in every way we can. They are at the heart of everything we do. We focus on providing treatments and services for patients with neurological, rare metabolic, and rare immunological conditions, most of which are genetic conditions. We’re headquartered in Cambridge, UK and have staff working across the US, with an office in Boston, MA.
- Website
-
http://www.cyclepharma.com/
External link for Cycle Pharmaceuticals
- Industry
- Pharmaceutical Manufacturing
- Company size
- 51-200 employees
- Headquarters
- Cambridge, Cambridgeshire
- Type
- Privately Held
- Founded
- 2012
- Specialties
- Rare Diseases, Pharmaceutical Industry, Formulation technology, Patient centric, Innovation, Research and Development, Tyrosinemia, Neurology, immunology , Multiple Sclerosis, HAE, PKU, MS, and cystineria
Locations
-
Primary
The Broers Building
21 JJ Thomson Avenue
Cambridge, Cambridgeshire CB3 0FA, GB
-
Boston, US
Employees at Cycle Pharmaceuticals
Updates
-
Cycle Pharmaceuticals reposted this
So proud that Cycle Pharmaceuticals is in the 2024 #SundayTimes100 list of the UK's fastest growing businesses. Shout out to the whole Cycle team. Shout out to everyone who has helped us on this incredible journey. Let's go again and help more and more people born with rare genetic diseases. "we've not come this far, to come this far"! David Buckeridge Steve Fuller Steve McCue Sarah Gowing Chikai Lai Romina Briffa, PhD Catherine Wainwright Chris Shaw Zac Bohlen #eoyuk Sumir Karayi Ally Scott Frank O'Keeffe Lynn Rattigan Courtney Shields Tim Davis Richard Tyler Ying van de Walle
-
-
Today is International #PKUDay. A day to raise awareness for Phenylketonuria, commonly known as PKU. PKU is a #RareGeneticDisorder that prevents the body from properly breaking down an amino acid called phenylalanine, found in many protein-containing foods. Without proper management this amino acid can build up in the blood and lead to serious health issues. Understanding PKU helps support those living with the disorder and their caregivers. Why June 28th? PKU Day takes place on June 28th because both Robert Gurthrie and Horst Bickel were born on this day in 1916 and 1918 respectively. Robert Gurthrie invented the possibility for newborn screening – also known as the “Guthrie test”. Horst Bickel was the firs to develop a low-protein diet for PKU and establish screening in Germany. To learn more about PKU and the importance of spreading awareness visit: https://lnkd.in/gHkpcSP
-
-
For our #MeetTheTeam post this month we’d like to introduce you to Rosie Collings who is part of our Regulatory Affairs team. “Knowing that my role makes a difference to patients and their families, contributing to patients’ safety is what gets me out of bed everyday ready to work.”
-
-
On Friday, James was interviewed by Dame Julia Hoggett, CEO of the London Stock Exchange at their headquarters in London. Be on the lookout for the video and podcast with the LSEG (London Stock Exchange Group) as part of their ‘Be Inspired’ #CEOseries. Here’s a glimpse behind the scenes!🎥
-
-
What an enjoyable and memorable week we had connecting in-person with our teams in the US and UK🙌. Our colleagues joined us at our headquarters in Cambridge for a week of networking and team building with a focus on High Performance and our mission at Cycle. From punting down the Cam, listening to Ben Shephard and Damian Hughes speak on High Performance, to hearing from colleagues sharing their own Cycle Story. It was a busy week, but we think we can speak for everyone and say it was worthwhile! Seeing everyone come together, collaborate, and share experiences was inspiring and a clear indicator of just how well we work together. A special thank you to everyone who was involved in organizing this event and Robinson College, Cambridge for hosting us – we are already looking forward to next year! #CyclePharma #BuildingOurFuture
-
-
-
-
-
+3
-
-
We’ve recently launched a treatment with patient support for patients in the US with cystinuria. But do you know what cystinuria is? 🤔 🔸A rare genetic disease. 🔸A chronic lifelong condition in which kidney stones commonly reoccur. 🔸The most common inheritable cause of kidney stone disease. 🔸It’s estimated to affect 1 in 7,000 people worldwide. Learn more about this treatment option in our press release: https://lnkd.in/evWDPaMr #Cystinuria #RareDisease #KidneyStones
-
-
You may have seen our recent news about our product for patients in the US with Primary Periodic Paralysis (PPP), but what exactly is PPP? 🤔 PPP is a rare disease that causes severe episodes of muscle weakness and/or temporary paralysis due to variations in blood potassium levels. It is caused by a genetic mutation which is normally inherited from a parent, although not everyone shows symptoms. There are four main types of PPP, which you can read more about in the images or at https://lnkd.in/ef-rUirA
-
-
Cycle Pharmaceuticals reposted this
On May 24, 2024, we made a proposal to the Board of Directors of Vanda Pharmaceuticals to acquire all issued and outstanding shares in the company. Our proposal would deliver immediate and certain cash value for Vanda shareholders. More importantly, we can help benefit patients, with our proven U.S. strategy and established track record of delivering medicines and individualized support to patients suffering from conditions with high unmet medical needs. We urge Vanda's shareholders to express their views on our proposal to the independent directors of the Vanda Board of Directors. https://lnkd.in/duxH3FHp
-
-
On May 24, 2024, we made a proposal to the Board of Directors of Vanda Pharmaceuticals to acquire all issued and outstanding shares in the company. Our proposal would deliver immediate and certain cash value for Vanda shareholders. More importantly, we can help benefit patients, with our proven U.S. strategy and established track record of delivering medicines and individualized support to patients suffering from conditions with high unmet medical needs. We urge Vanda's shareholders to express their views on our proposal to the independent directors of the Vanda Board of Directors. https://lnkd.in/duxH3FHp
-